GS-9716

News alerts, weekly reports and conference planners

Company:

Gilead

Drug class:

MCL1 inhibitor

Related drugs:

5ms

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies (clinicaltrials.gov)

P1, N=195, Recruiting, Gilead Sciences

5 months ago

Trial completion date • Trial primary completion date • Combination therapy

docetaxel • Trodelvy (sacituzumab govitecan-hziy) • GS-9716

2years

GS-9716: A potent, selective and orally bioavailable small molecule inhibitor of MCL1 for the treatment of cancer (AACR 2022)

In addition to single agent activity, GS-9716 showed strong synergy with multiple anti-cancer therapies; robust in vitro synergy was observed with venetoclax in the AML models and as well as with paclitaxel in the TNBC models. Similar responses were also observed when GS-9716 was dosed with paclitaxel in the TNBC PDX models. GS-9716 is currently in Phase 1 clinical trial evaluating safety, tolerability and pharmacokinetics as monotherapy and in combination with anticancer therapies in adults with advanced solid tumors (NCT05006794).

2 years ago

IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1)

Venclexta (venetoclax) • paclitaxel • GS-9716